Carregant...

Gemcitabine and taxanes in metastatic breast cancer: a systematic review

Incremental advances over the last two decades in the treatment of stage IV metastatic breast cancer (MBC) have resulted in significantly prolonging the average life expectancy. In 2008, the estimated 5-year relative survival rate for MBC is 27% which compares favorably to rates in stage IV lung (3%...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gudena, Vinay, Montero, Alberto J, Glück, Stefan
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2643097/
https://ncbi.nlm.nih.gov/pubmed/19337423
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!